Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN49849003
ISRCTN49849003
Completed
Not Applicable

A proof-of-concept study to evaluate the benefit from add-on therapy with montelukast versus salmeterol in children with asthma carrying the Arg/Arg-16 beta2-receptor genotype

niversity of Dundee (UK)0 sites120 target enrollmentJuly 31, 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
niversity of Dundee (UK)
Enrollment
120
Status
Completed
Last Updated
11 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 31, 2008
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity of Dundee (UK)

Eligibility Criteria

Inclusion Criteria

  • •All children and adolescents (5 \- 18 years, either sex) with asthma in Tayside (Scotland) known:
  • •1\. To carry the Arg/Arg\-16 genotype, and
  • •2\. Currently on inhaled steroids, and
  • •3\. Inhaled bronchodilators according to need
  • •Will be telephoned or contacted through home visits to establish if they have had:
  • •1\. Any school absences from asthma, or
  • •2\. Out\-of\-hours visits to General Practitioner (GP)/hospital visits or admissions due to asthma over the previous 12 months

Exclusion Criteria

  • •The presence of serious respiratory or multi\-system disease (e.g. cystic fibrosis, cancer under current treatment)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A Proof-of-Concept Study to evaluate the benefit from add-on therapy with montelukast versus salmeterol in children with asthma carrying the Arg/Arg-16 beta2-receptor genotypeAsthmaMedDRA version: 8.1Level: LLTClassification code 10003553Term: Asthma
EUCTR2006-003264-65-GBniversity of Dundee
Completed
Not Applicable
A Randomised, Double-blinded, Placebo-controlled Study of the probiotic PCC(Registered Trademark) (L. fermentum VRI-003) capsule for the effect on gastrointestinal health and gut microflora in healthy adults (with no medically diagnosed gastrointestinal disease)Gastrointestinal healthOral and Gastrointestinal - Normal oral and gastrointestinal development and function
ACTRN12616001052426Bioxyne Limited60
Completed
Not Applicable
A proof of concept study to evaluate the impact of a food supplement on uptake and anti-inflammatory properties of omega-3 fatty acid derived specialized pro-resolution lipid mediatorsHealthy volunteers
DRKS00023304Evonik Operations GmbH19
Completed
Not Applicable
A proof of concept study to evaluate the impact of a food supplement on production of short chain fatty acids and microbiome in healthy subjectshealthy volunteers
DRKS00023166Evonik Operations GmbH18
Active, not recruiting
Phase 1
A proof-of-concept study to assess the effect of ACT-451840 against early Plasmodium falciparum blood stage infection in healthy subjects.MalariaInfection - Other infectious diseases
ACTRN12614000781640James McCarthy8